The stock of Cyclerion Therapeutics Inc (CYCN) has seen a -13.83% decrease in the past week, with a -9.17% drop in the past month, and a -13.15% decrease in the past quarter. The volatility ratio for the week is 19.46%, and the volatility levels for the past 30 days are at 17.49% for CYCN. The simple moving average for the last 20 days is -17.71% for CYCN stock, with a simple moving average of -24.75% for the last 200 days.
Is It Worth Investing in Cyclerion Therapeutics Inc (NASDAQ: CYCN) Right Now?
The 36-month beta value for CYCN is also noteworthy at 1.87. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CYCN is 2.08M, and at present, short sellers hold a 0.69% of that float. The average trading volume of CYCN on November 15, 2024 was 16.09K shares.
CYCN) stock’s latest price update
The stock price of Cyclerion Therapeutics Inc (NASDAQ: CYCN) has surged by 23.16 when compared to previous closing price of 1.77, but the company has seen a -13.83% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-07 that CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.
Analysts’ Opinion of CYCN
Many brokerage firms have already submitted their reports for CYCN stocks, with Truist repeating the rating for CYCN by listing it as a “Buy.” The predicted price for CYCN in the upcoming period, according to Truist is $14 based on the research report published on October 20, 2021 of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see CYCN reach a price target of $7. The rating they have provided for CYCN stocks is “Overweight” according to the report published on September 24th, 2021.
CYCN Trading at -18.51% from the 50-Day Moving Average
After a stumble in the market that brought CYCN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.48% of loss for the given period.
Volatility was left at 17.49%, however, over the last 30 days, the volatility rate increased by 19.46%, as shares sank -10.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.55% lower at present.
During the last 5 trading sessions, CYCN fell by -11.46%, which changed the moving average for the period of 200-days by -41.51% in comparison to the 20-day moving average, which settled at $2.6522. In addition, Cyclerion Therapeutics Inc saw -34.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CYCN
The total capital return value is set at -1.23. Equity return is now at value -150.23, with -103.82 for asset returns.
Currently, EBITDA for the company is -12.59 million with net debt to EBITDA at 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.68.
Conclusion
In summary, Cyclerion Therapeutics Inc (CYCN) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
